

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 July 2024 (25.07.2024)



(10) International Publication Number
WO 2024/155565 A2

- (51) **International Patent Classification:**
C07D 515/22 (2006.01) *A61K 47/68* (2017.01)
- (21) **International Application Number:**
PCT/US2024/011578
- (22) **International Filing Date:**
16 January 2024 (16.01.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/480,285 17 January 2023 (17.01.2023) US
- (71) **Applicant:** **YARROW THERAPEUTICS, INC.**
[US/US]; 3031 Tisch Way, Suite 605, San Jose, California
95128 (US).
- (72) **Inventor:** **GAVRILYUK, Julia**; 3031 Tisch Way, Suite
605, San Jose, California 95128 (US).
- (74) **Agent:** **LOHREY, Trevor** et al.; Wilson Sonsini Goodrich
& Rosati, 650 Page Mill Road, Palo Alto, California 94304
(US).
- (81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))*

Published:

— *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title:** ECTEINASCIDIN DERIVATIVE ANTIBODY DRUG CONJUGATES




FIG. 1

(57) **Abstract:** Provided herein are compounds, methods, and pharmaceutical compositions for use in treatment of cancer. In certain embodiments, ecteinascidin derivative antibody drug conjugate compounds are provided which display remarkable efficacy and bioavailability for the treatment of, for example, cancer in a human.



WO 2024/155565 A2